» Articles » PMID: 8943413

Loss of Either CD4+ or CD8+ T Cells Does Not Affect the Magnitude of Protective Immunity to an Intracellular Pathogen, Francisella Tularensis Strain LVS

Overview
Journal J Immunol
Date 1996 Dec 1
PMID 8943413
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Normal mice readily survive a sublethal intradermal (i.d.) infection with Francisella tularensis live vaccine strain (LVS), a model intracellular bacterium, and are strongly protected against subsequent lethal challenge. However, athymic nu/nu mice, which lack mature alphabeta TCR+ T lymphocytes, succumb to i.d. infection within 30 days. Here we characterize the alphabeta T cell subpopulations necessary for both resolution of i.d. infection and generation of optimal protective immunity to LVS. BALB/cByJ mice treated with anti-CD4 or anti-CD8 Abs before i.d. infection survived and cleared bacteria, and anti-CD4- or anti-CD8-treated immune mice survived a very strong i.p. challenge of 10,000 LD50s. Among mutant mice with targeted gene disruptions (knockouts), CD4-, beta2-microglobulin-deficient (which are also CD8-), and gammadelta TCR- mice all resolved a large sublethal i.d. infection. All CD4- and beta2-microglobulin-deficient mice readily survived subsequent lethal i.p. challenge of 10,000 LD50s, even in the absence of specific IgG Abs, as did most (86%) gammadelta TCR- mice. In contrast, alphabeta TCR- mice or alphabeta + gammadelta TCR- mice died about 35 days after i.d. infection. Depletion of gammadelta+ T cells from alphabeta TCR- mice had no effect on mean time to death from i.d. LVS infection. Therefore alphabeta TCR+ cells are required for protection, but either CD4+ or CD8+ T cells are individually sufficient to resolve a large sublethal i.d. LVS infection and to protect against a maximal secondary lethal challenge. These results emphasize the remarkable plasticity of the alphabeta T cell response in protective immunity to intracellular bacteria.

Citing Articles

Circulating T Cells Are Not Sufficient for Protective Immunity against Virulent .

Roberts L, Wehrly T, Leighton I, Hanley P, Lovaglio J, Smith B J Immunol. 2022; 208(5):1180-1188.

PMID: 35149529 PMC: 8881340. DOI: 10.4049/jimmunol.2100915.


Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.

Salerno-Goncalves R, Chen W, Mulligan M, Frey S, Stapleton J, Keitel W Clin Transl Immunology. 2021; 10(1):e1239.

PMID: 33505681 PMC: 7814273. DOI: 10.1002/cti2.1239.


Early infection-induced natural antibody response.

Kubelkova K, Hudcovic T, Kozakova H, Pejchal J, Macela A Sci Rep. 2021; 11(1):1541.

PMID: 33452341 PMC: 7810682. DOI: 10.1038/s41598-021-81083-0.


Glycoconjugate vaccine using a genetically modified O antigen induces protective antibodies to .

Stefanetti G, Okan N, Fink A, Gardner E, Kasper D Proc Natl Acad Sci U S A. 2019; 116(14):7062-7070.

PMID: 30872471 PMC: 6452683. DOI: 10.1073/pnas.1900144116.


Host restriction of Escherichia coli recurrent urinary tract infection occurs in a bacterial strain-specific manner.

OBrien V, Dorsey D, Hannan T, Hultgren S PLoS Pathog. 2018; 14(12):e1007457.

PMID: 30543708 PMC: 6292575. DOI: 10.1371/journal.ppat.1007457.